<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p201" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_201{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_201{left:306px;bottom:30px;}
#t3_201{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_201{left:346px;bottom:30px;}
#t5_201{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_201{left:517px;bottom:30px;}
#t7_201{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_201{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_201{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_201{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_201{left:35px;bottom:777px;letter-spacing:0.08px;word-spacing:-0.57px;}
#tc_201{left:35px;bottom:754px;letter-spacing:0.06px;word-spacing:-0.87px;}
#td_201{left:35px;bottom:731px;letter-spacing:0.11px;word-spacing:-0.17px;}
#te_201{left:35px;bottom:707px;letter-spacing:0.11px;word-spacing:0.07px;}
#tf_201{left:35px;bottom:684px;letter-spacing:0.21px;word-spacing:-0.02px;}
#tg_201{left:35px;bottom:661px;letter-spacing:0.13px;word-spacing:0.05px;}
#th_201{left:144px;bottom:668px;letter-spacing:-0.01px;}
#ti_201{left:167px;bottom:661px;letter-spacing:0.18px;word-spacing:0.01px;}
#tj_201{left:35px;bottom:638px;letter-spacing:0.14px;word-spacing:-0.63px;}
#tk_201{left:35px;bottom:614px;letter-spacing:0.06px;word-spacing:0.12px;}
#tl_201{left:35px;bottom:591px;letter-spacing:0.09px;word-spacing:-0.68px;}
#tm_201{left:395px;bottom:599px;letter-spacing:-0.01px;}
#tn_201{left:417px;bottom:591px;letter-spacing:0.04px;word-spacing:-0.17px;}
#to_201{left:35px;bottom:568px;letter-spacing:0.03px;word-spacing:-0.07px;}
#tp_201{left:35px;bottom:545px;letter-spacing:0.15px;word-spacing:0.04px;}
#tq_201{left:35px;bottom:507px;letter-spacing:-0.1px;word-spacing:0.54px;}
#tr_201{left:35px;bottom:484px;letter-spacing:0.06px;word-spacing:0.13px;}
#ts_201{left:35px;bottom:460px;letter-spacing:0.27px;word-spacing:-0.08px;}
#tt_201{left:251px;bottom:460px;letter-spacing:0.21px;word-spacing:-0.03px;}
#tu_201{left:35px;bottom:437px;letter-spacing:0.17px;word-spacing:-1.21px;}
#tv_201{left:208px;bottom:437px;letter-spacing:0.04px;word-spacing:-0.88px;}
#tw_201{left:35px;bottom:414px;letter-spacing:-0.33px;word-spacing:1.72px;}
#tx_201{left:125px;bottom:414px;letter-spacing:0.06px;}
#ty_201{left:246px;bottom:414px;letter-spacing:0.43px;}
#tz_201{left:35px;bottom:374px;letter-spacing:0.42px;}
#t10_201{left:86px;bottom:374px;letter-spacing:0.1px;word-spacing:-0.87px;}
#t11_201{left:35px;bottom:350px;letter-spacing:0.14px;word-spacing:0.06px;}
#t12_201{left:149px;bottom:350px;letter-spacing:0.07px;word-spacing:0.11px;}
#t13_201{left:35px;bottom:327px;letter-spacing:0.04px;word-spacing:0.15px;}
#t14_201{left:35px;bottom:304px;letter-spacing:0.03px;word-spacing:0.16px;}
#t15_201{left:35px;bottom:281px;letter-spacing:0.17px;word-spacing:0.01px;}
#t16_201{left:35px;bottom:258px;letter-spacing:0.09px;word-spacing:0.1px;}
#t17_201{left:472px;bottom:258px;letter-spacing:0.23px;word-spacing:-0.05px;}
#t18_201{left:35px;bottom:234px;letter-spacing:0.1px;word-spacing:-0.43px;}
#t19_201{left:35px;bottom:211px;letter-spacing:0.36px;}
#t1a_201{left:94px;bottom:211px;letter-spacing:0.19px;}
#t1b_201{left:337px;bottom:219px;letter-spacing:-0.01px;}
#t1c_201{left:361px;bottom:211px;letter-spacing:0.18px;word-spacing:0.01px;}
#t1d_201{left:35px;bottom:188px;letter-spacing:0.09px;word-spacing:0.09px;}
#t1e_201{left:35px;bottom:165px;letter-spacing:-0.01px;word-spacing:0.54px;}
#t1f_201{left:35px;bottom:141px;letter-spacing:-0.02px;word-spacing:0.21px;}
#t1g_201{left:324px;bottom:149px;letter-spacing:-0.01px;}
#t1h_201{left:350px;bottom:141px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1i_201{left:35px;bottom:118px;letter-spacing:-0.01px;word-spacing:0.56px;}
#t1j_201{left:35px;bottom:95px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1k_201{left:618px;bottom:777px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1l_201{left:618px;bottom:754px;letter-spacing:0.18px;word-spacing:0.01px;}
#t1m_201{left:618px;bottom:713px;letter-spacing:0.43px;}
#t1n_201{left:618px;bottom:685px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1o_201{left:618px;bottom:662px;letter-spacing:0.09px;word-spacing:-1.13px;}
#t1p_201{left:843px;bottom:662px;letter-spacing:0.13px;word-spacing:-0.29px;}
#t1q_201{left:618px;bottom:639px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1r_201{left:618px;bottom:616px;letter-spacing:0.02px;word-spacing:0.16px;}
#t1s_201{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_201{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_201{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_201{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_201{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_201{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_201{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_201{font-size:17px;font-family:ArialMT_k0;color:#000;}
.s7_201{font-size:16px;font-family:Arial-BoldItalicMT_kg;color:#000;}
.s8_201{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s9_201{font-size:17px;font-family:ArialMT_5tg;color:#005B99;}
.sa_201{font-size:17px;font-family:ArialMT_5tg;color:#202020;}
.sb_201{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts201" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_kg;
	src: url("fonts/Arial-BoldItalicMT_kg.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg201Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg201" style="-webkit-user-select: none;"><object width="1210" height="935" data="201/201.svg" type="image/svg+xml" id="pdf201" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_201" class="t s0_201">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_201" class="t s1_201">© </span>
<span id="t3_201" class="t s0_201">(NCCN </span>
<span id="t4_201" class="t s1_201">© </span>
<span id="t5_201" class="t s0_201">), All rights reserved. NCCN Guidelines </span>
<span id="t6_201" class="t s1_201">® </span>
<span id="t7_201" class="t s0_201">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_201" class="t s2_201">NCCN Guidelines Version 4.2024 </span>
<span id="t9_201" class="t s2_201">Head and Neck Cancers </span>
<span id="ta_201" class="t s3_201">MS-60 </span>
<span id="tb_201" class="t s4_201">suggest that the use of hypofractionation in cutaneous melanomas (which </span>
<span id="tc_201" class="t s4_201">is convenient) is associated with good outcomes but no clear advantage in </span>
<span id="td_201" class="t s4_201">cancer control. Little experience is available using large dose per fraction </span>
<span id="te_201" class="t s4_201">in mucosal sites. Because of the close proximity of neural structures and </span>
<span id="tf_201" class="t s4_201">risk of late effects, hypofractionation (if used) must be carefully planned </span>
<span id="tg_201" class="t s4_201">and delivered. </span>
<span id="th_201" class="t s5_201">763 </span>
<span id="ti_201" class="t s4_201">RT should not be used concurrently with BRAF/MEK </span>
<span id="tj_201" class="t s4_201">inhibitor therapy, as concurrent use has been found to be associated with </span>
<span id="tk_201" class="t s6_201">grade ≥3 dermatologic reactions, and potentially lethal hemorrhaging in </span>
<span id="tl_201" class="t s4_201">the liver, lung, and brain have all been reported. </span>
<span id="tm_201" class="t s5_201">764 </span>
<span id="tn_201" class="t s4_201">For primary sites in the </span>
<span id="to_201" class="t s4_201">paranasal sinuses and nasal cavity, PBT should be considered due to the </span>
<span id="tp_201" class="t s4_201">proximity of eye and other vital structures. </span>
<span id="tq_201" class="t s7_201">Systemic Therapy </span>
<span id="tr_201" class="t s4_201">Systemic therapy used for cutaneous melanoma (eg, immunotherapy) is </span>
<span id="ts_201" class="t s4_201">recommended for MM (see </span><span id="tt_201" class="t s8_201">Systemic Therapy for Metastatic or </span>
<span id="tu_201" class="t s8_201">Unresectable Disease </span><span id="tv_201" class="t s4_201">in the NCCN Guidelines for Melanoma: Cutaneous, </span>
<span id="tw_201" class="t s4_201">available at </span><span id="tx_201" class="t s9_201">www.NCCN.org</span><span id="ty_201" class="t s4_201">). </span>
<span id="tz_201" class="t s4_201">There </span><span id="t10_201" class="t sa_201">is currently no standard approach for systemic therapy treatment of </span>
<span id="t11_201" class="t sa_201">resectable MM</span><span id="t12_201" class="t s4_201">. Adjuvant systemic immunotherapy is an option for MM </span>
<span id="t13_201" class="t s4_201">with nodal involvement. While the majority of patients in melanoma </span>
<span id="t14_201" class="t s4_201">adjuvant trials had cutaneous primaries, some patients with MM were </span>
<span id="t15_201" class="t s4_201">included. Neoadjuvant checkpoint inhibitor for MM is not well-studied. </span>
<span id="t16_201" class="t s4_201">Recent data suggest, however, that neoadjuvant therapy </span><span id="t17_201" class="t sa_201">for resectable </span>
<span id="t18_201" class="t sa_201">MM is a feasible approach with signs of efficacy and an acceptable safety </span>
<span id="t19_201" class="t sa_201">profile. </span><span id="t1a_201" class="t s4_201">Further investigation is needed. </span>
<span id="t1b_201" class="t s5_201">765 </span>
<span id="t1c_201" class="t s4_201">More recently, data </span>
<span id="t1d_201" class="t s4_201">demonstrate improvements in event-free survival with neoadjuvant and </span>
<span id="t1e_201" class="t s4_201">adjuvant pembrolizumab over adjuvant pembrolizumab alone in patients </span>
<span id="t1f_201" class="t s4_201">with resectable stage III/IV melanoma. </span>
<span id="t1g_201" class="t s5_201">766 </span>
<span id="t1h_201" class="t s4_201">While this study included only a </span>
<span id="t1i_201" class="t s4_201">small number of patients with mucosal melanoma, it is not known </span>
<span id="t1j_201" class="t s4_201">whether this approach is of value for this particular melanoma subtype, </span>
<span id="t1k_201" class="t s4_201">though it may be useful in certain situations (ie, large symptomatic </span>
<span id="t1l_201" class="t s4_201">disease burden). </span>
<span id="t1m_201" class="t s3_201">Follow-up </span>
<span id="t1n_201" class="t s4_201">Recommendations for surveillance are provided in the algorithm (see </span>
<span id="t1o_201" class="t s8_201">Follow-up Recommendations </span><span id="t1p_201" class="t s4_201">in the NCCN Guidelines for Head and Neck </span>
<span id="t1q_201" class="t s4_201">Cancers). Note that physical examination for MM should include </span>
<span id="t1r_201" class="t s4_201">endoscopic inspection for nasal cavity and paranasal sinus disease. </span>
<span id="t1s_201" class="t sb_201">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
